Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells

BACKGROUND: Proteasome inhibitors are attractive cancer therapeutic agents because they can regulate apoptosis-related proteins. Bortezomib also known as Velcade(®), a proteasome inhibitor that has been approved by the food and drug administration for treatment of patients with multiple myeloma, and...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Transl Med
Hlavní autoři: Iskandarani, Ahmad, Bhat, Ajaz A., Siveen, Kodappully S., Prabhu, Kirti S., Kuttikrishnan, Shilpa, Khan, Muzammil A., Krishnankutty, Roopesh, Kulinski, Michal, Nasr, Rihab R., Mohammad, Ramzi M., Uddin, Shahab
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2016
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4784454/
https://ncbi.nlm.nih.gov/pubmed/26956626
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-016-0823-y
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky